“Our collaboration with Dicerna to discover and develop GalXC RNAi therapies, which have the potential to inhibit uncontrolled activation of the complement system in new ways, represents an exciting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback